A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib (BAY 43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens.

Trial Profile

A Phase III, Multi-Center, Placebo-Controlled Trial of Sorafenib (BAY 43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MISSION
  • Sponsors Bayer
  • Most Recent Events

    • 01 Dec 2015 Results published in the Journal of Thoracic Oncology
    • 06 Nov 2015 Results published in the Journal of Thoracic Oncology
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top